Found 154 articles
Healthy male participants who take a novel antioxidant that specifically targets the powerhouse of the cells, mitochondria, sees attenuation in exercise induced mitochondria DNA (mtDNA) damage in lymphocytes and muscle.
KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors
KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced dosing of the first patient in its Phase 1/2 clinical trial assessing its lead product, DSP107, a bi-functional CD47x41BB candidate for the treatment of solid tumors.
FASENRA® eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE Phase IIIb trial
FASENRA ® eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE Phase IIIb trial 62% of patients stopped OCS use in largest ever steroid sparing trial in severe asthma
A patient with end-stage and rapidly progressing soft-tissue cancer whose tumor did not respond to standard treatment, had a "rapid and complete response" to a novel combination of immunotherapy, according to new research published by a team of scientists from John Theurer Cancer Center at Hackensack University Medical Center
Prof. Hagop M. Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, has joined KAHR's clinical advisory board.
Data for DSP107, first-in-class bi-functional CD47x41BB targeting compound, to be presented on December 5, 2020
KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced that Aron Knickerbocker has been appointed Director and that Bryan Jennings has been appointed Chief Financial Officer of KAHR.
Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020
Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors
Dr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. Market
Dr. Reddy’s Laboratories Ltd. announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a therapeutic equivalent generic version of Concerta® Extended-Release Tablets, 18 mg, 27 mg, 36 mg, and 54 mg, approved by the U.S.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2020 and provided a business update.
Predictive Oncology Issues Letter to ShareholdersAnnual Meeting of Stockholders to be Held on September 3, 2020
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today issued a letter to shareholders discussing the Company’s recent accomplishments and voting recommendations from its Board of Directors for two proposals that are scheduled for shareholder vote on September 3, 2020.
ORTIKOS™ (budesonide), the First and Only Once-Daily Dose for Treatment of Mild to Moderate Crohn’s Disease, Now Available in the U.S.
ORTIKOS ™ (budesonide), the First and Only Once-Daily Dose for Treatment of Mild to Moderate Crohn’s Disease, Now Available in the U.S. ORTIKOS is available in one convenient pill in two dosage strengths (9mg, 6mg) for the treatment of mild to moderate active Crohn’s disease in patients 8 years and older and maintenance of clinical remission for up to three months in adults 1 Approximately 800,000 Americans are currently living with Crohn’s
AMRA Medical – global leader in body composition profiling – will collaborate with the National University of Singapore's (NUS) Yong Loo Lin School of Medicine on an Asian-centric study to enhance the understanding of Non-Alcoholic Fatty Liver Disease (NAFLD).
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid tumors Prodrug XPATs demonstrated >1000 fold increase in tolerated exposures versus traditional T cell engagers Amunix’s lead program, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors, continues to progress toward the clinic MOUNTAIN VIEW, Calif., June 22, 2020 (GLOBE NEWS
Predictive Oncology Inc. (NASDAQ: POAI) (the “Company”) a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the acquisition of the assets of Soluble Therapeutics, Inc. and BioDtech, Inc., each of which is a wholly-owned subsidiary of InventaBioTech, Inc.
Today, the Association of Black Cardiologists (ABC) issued frequently asked questions (FAQ Watch) for healthcare providers related to COVID-19.
Incyte Partners with Artist and Patient J.G. Jones to Raise Awareness for Myeloproliferative Neoplasms (MPNs)
Incyte announces launch of “Rare Reflections: MPNs Unmasked” as part of its ongoing efforts to raise awareness of MPNs.
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has made two appointments to strengthen its leadership team, as the Company positions itself for growth.
Generex Biotechnology Appoints Independent Directors Craig Eagle, MD and Thomas Leonard to the NuGenerex Immuno-Oncology Board of Directors
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointments of Dr. Craig Eagle, MD and Mr. Thomas Leonard to the NuGenerex Immuno-Oncology (NGIO) Board of Directors.
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Boehringer Ingelheim's discovery programmes